Based on these developments, currentguidelines from the ESC and AHA/ACC/HFSA strongly supports a quadruple therapyregimen comprising the above novel agents combined with conventionalbeta-blockers and mineralocorticoid receptor antagonists (MRAs) for managing HF[7, 8]. Here, NR3C2 is linked to hydrops fetalis.